- Home
- EDIT vs NA Comparison
EDIT vs NA Comparison
Compare EDIT & NA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- NA
- Stock Information
- Founded
- EDIT 2013
- NA 2019
- Country
- EDIT United States
- NA China
- Employees
- EDIT N/A
- NA N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- NA Semiconductors
- Sector
- EDIT Health Care
- NA Technology
- Exchange
- EDIT Nasdaq
- NA Nasdaq
- Market Cap
- EDIT 99.9M
- NA 109.1M
- IPO Year
- EDIT 2016
- NA 2022
- Fundamental
- Price
- EDIT $1.21
- NA $7.86
- Analyst Decision
- EDIT Buy
- NA
- Analyst Count
- EDIT 14
- NA 0
- Target Price
- EDIT $8.08
- NA N/A
- AVG Volume (30 Days)
- EDIT 2.7M
- NA 464.4K
- Earning Date
- EDIT 02-26-2025
- NA 03-17-2025
- Dividend Yield
- EDIT N/A
- NA N/A
- EPS Growth
- EDIT N/A
- NA N/A
- EPS
- EDIT N/A
- NA N/A
- Revenue
- EDIT $61,759,000.00
- NA $6,991,446.00
- Revenue This Year
- EDIT N/A
- NA N/A
- Revenue Next Year
- EDIT N/A
- NA N/A
- P/E Ratio
- EDIT N/A
- NA N/A
- Revenue Growth
- EDIT 150.95
- NA N/A
- 52 Week Low
- EDIT $1.12
- NA $2.75
- 52 Week High
- EDIT $11.58
- NA $47.50
- Technical
- Relative Strength Index (RSI)
- EDIT 34.86
- NA 49.35
- Support Level
- EDIT $1.15
- NA $6.99
- Resistance Level
- EDIT $1.27
- NA $8.95
- Average True Range (ATR)
- EDIT 0.10
- NA 0.88
- MACD
- EDIT 0.04
- NA -0.04
- Stochastic Oscillator
- EDIT 21.11
- NA 31.88
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.